GRAIL INC. DL-,01 Aktie

GRAL's Galleri test is easily its main value driver at this point. This test can screen over 50 cancers with high sensitivity and accuracy. Post-spin-off from Illumina, GRAL has continued growing its revenues while also securing partnerships like Quest Diagnostics and TRICARE. GRAL's Galleri also secured the FDA's Breakthrough Device status, and its pivotal PMA submission should happen by 1H2026.» Mehr auf seekingalpha.com

GRAIL, Inc.'s Galleri test could see significant revenue growth if the bipartisan MCED bill passes, enabling Medicare reimbursement for FDA-approved multi-cancer early detection tests. Galleri's potential market includes 67 million Medicare beneficiaries, with a conservative estimate of $2.4 billion in revenue by the fifth year post-legislation. Despite promising financials and market leadership, Galleri's FDA approval is pending, and Medicare reimbursement may not start until 2028, posing short-term risks.» Mehr auf seekingalpha.com

MENLO PARK, Calif. , Feb. 26, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 108,450 shares of GRAIL's common stock to 15 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL.» Mehr auf prnewswire.com